Skip to main content

Main menu

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
  • Other Publications
    • www.clevelandclinic.org

User menu

  • Register
  • Log in

Search

  • Advanced search
Cleveland Clinic Journal of Medicine
  • Other Publications
    • www.clevelandclinic.org
  • Register
  • Log in
Cleveland Clinic Journal of Medicine

Advanced Search

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022

More articles from Current Drug Therapy

  • You have access
    Using viral load, CD4+ levels, and clinical response to guide antiviral therapy for HIV
    Leonard H. Calabrese, DO
    Cleveland Clinic Journal of Medicine May 2000, 67 (5) 321-328;

    A summary of the most recent guidelines from the International AIDS Society.

  • You have access
    Inhibitors of tumor necrosis factor: New treatment options for rheumatoid arthritis
    Larry W. Moreland, MD
    Cleveland Clinic Journal of Medicine June 1999, 66 (6) 367-374;

    The treatment of autoimmune diseases took a big step forward recently with the release of new drugs that target one of the key cytokines in the inflammatory process. With an illustration showing how the new drugs block tumor necrosis factor.

  • You have access
    COX 2-selective NSAIDs: Biology, promises, and concerns
    Brian F. Mandell, MD, PhD
    Cleveland Clinic Journal of Medicine May 1999, 66 (5) 285-292;

    A new family of nonsteroidal anti-inflammatory drugs promises to be substantially safer than current agents, but should not be assumed to be totally without adverse effects.

  • You have access
    Hypersensitivity syndrome to antiepileptic drugs: A review including new anticonvulsants
    Hajo M. Hamer, MD and Harold H. Morris, MD
    Cleveland Clinic Journal of Medicine April 1999, 66 (4) 239-245;

    How to recognize this potentially fatal adverse reaction and choose a safe substitute drug.

  • You have access
    Antileukotrienes and asthma: Alternative or adjunct to inhaled steroids?
    Mani S. Kavuru, MD, Revathi Subramony, RPH and Ana R. Vann, PharmD
    Cleveland Clinic Journal of Medicine November 1998, 65 (10) 519-526;

    A new class of oral drugs decrease airway inflammation and constriction. An illustration shows how the new antileukotriene drugs block the process of airway inflammation.

  • You have access
    Lipid formulations of amphotericin B
    Edward Jones, PharmD and Morton Goldman, PharmD
    Cleveland Clinic Journal of Medicine September 1998, 65 (8) 423-427;

    New lipid formulations of amphotericin B are less nephrotoxic and can he given in higher doses than standard formulations, but improved efficacy has not been proved. With an illustration explaining the pharmacokinetics of these preparations.

  • You have access
    Sildenafil (Viagra) for treating male erectile dysfunction
    Mark R. Licht, MD
    Cleveland Clinic Journal of Medicine June 1998, 65 (6) 301-304;

    A brief overview of sildenafil, the first oral drug for treating erectile dysfuntion. With an illustration showing how the drug works.

  • You have access
    What internists should know about amiodarone
    Mark T. Murphy, MB and Bruce L. Wilkoff, MD
    Cleveland Clinic Journal of Medicine March 1998, 65 (3) 159-166;

    Despite side effects involving the lungs, heart, thyroid, and other organs, amiodarone is effective in the treatment of refractory atrial and ventricular arrhythmias, and it has unique safety in coronary disease and left ventricular dysfunction.

  • You have access
    Protoivpump inhibitors for gastric acid-related disease
    Thomas G. Franko, MS and Joel E. Richter, MD
    Cleveland Clinic Journal of Medicine January 1998, 65 (1) 27-34;

    Proton-pump inhibitors are the most effective drugs for suppressing gastric acid production. Concerns over potential ill effects of hypergastrinemia have proved unfounded.

  • You have access
    Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
    Ray W. Gifford, MD
    Cleveland Clinic Journal of Medicine January 1998, 65 (1) 18-24;

    The JNC VI report updates the standard of care in hypertension, advising physicians to be more diligent in lowering blood pressure, especially in patients with known risk factors.

Pages

  • Previous
  • Next
  • 1
  • …
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • …
  • 14

Navigate

  • Current Issue
  • Past Issues
  • Supplements
  • Article Type
  • Specialty
  • CME/MOC Articles
  • CME/MOC Calendar
  • Media Kit

Authors & Reviewers

  • Manuscript Submission
  • Authors & Reviewers
  • Subscriptions
  • About CCJM
  • Contact Us
  • Cleveland Clinic Center for Continuing Education
  • Consult QD

Share your suggestions!

Copyright © 2025 The Cleveland Clinic Foundation. All rights reserved. The information provided is for educational purposes only. Use of this website is subject to the website terms of use and privacy policy. 

Powered by HighWire